Treatment patterns in inpatients with bipolar disorder at a psychiatric university hospital over a 9-year period: Focus on mood stabilizers

International Clinical Psychopharmacology

Volumn 27, Issue 5, 2012, Pages 256-266

  Walpoth Niederwanger, Michaela ^a   Kemmler, Georg ^a   Grunze, Heinz ^b   Weiß, Ulrike ^a   Hörtnagl, Christine ^a   Strauß, Robert ^a   Blasko, Imrich ^a   Hausmann, Armand ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

bipolar disorder; evidence based medicine; mood stabilizers; sex difference; treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; FLUOXETINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; OXCARBAZEPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE;

ADULT; ARTICLE; AWARENESS; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIRTH DEFECT; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DECREASED APPETITE; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEMALE; GASTROINTESTINAL SYMPTOM; GENDER; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MENTAL HOSPITAL; MENTAL PATIENT; METABOLISM; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RESTLESSNESS; RETROSPECTIVE STUDY; SEDATION; SEX DIFFERENCE; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; AUSTRIA; BIPOLAR DISORDER; COHORT STUDIES; COMBINED MODALITY THERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES;

EID: 84864719318     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328356ac92     Document Type: Article

References (90)

1. Aichhorn W, Whitworth AB, Weiss EM, Hinterhuber H, Marksteiner J (2007). Differences between men and women in side effects of second-generation antipsychotics. Nervenarzt 78:45-52. (Pubitemid 46154504)
2. American Psychiatric Association (1994). Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 151:1-36.
3. American Psychiatric Association (2002). Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159:1-50.
4. American Psychiatric Association (2004). American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders. Arlington, VA: American Psychiatric Publishing Inc.
5. Anderson J (2000). On variability of effects for a metaanalysis of rheumatoid arthritis radiographic progression. J Rheumatol 27:540-542, discussion 542-543.
6. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L (2008). Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv 59:1175-1183.
7. Baldessarini RJ (2010). Commentary: the Bipolar Affective Disorder: Lithium/Anticonvulsant Evaluation (BALANCE) study. Bipolar Disord 12:669-672.
8. Bauer MS, Mitchner L (2004). What is a 'mood stabilizer'? An evidence-based response. Am J Psychiatry 161:3-18. (Pubitemid 38419301)
9. Bond DJ, Lam RW, Yatham LN (2010). Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord 124:228-234.
10. Bowden CL (2009). Anticonvulsants in bipolar disorders: current research and practice and future directions. Bipolar Disord 11 (Suppl 2):20-33.
11. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, et al.; Lamictal 606 Study Group (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 60:392-400. (Pubitemid 36403000)
12. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, et al. (2005). A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 66:111-121.
13. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M (2010). Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 71:130-137.
14. Bramness JG, Grøholt B, Engeland A, Furu K (2009). The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004-2007-a prescription database study. J Affect Disord 117:208-211.
15. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 60:79-88. (Pubitemid 29104383)
16. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, et al.; Lamictal 605 Study Group (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 64:1013-1024. (Pubitemid 37158246)
17. Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA,Weisler RH, et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162:1351-1360. (Pubitemid 40905587)
18. Calabrese JR, Huffman RF,White RL, Edwards S, Thompson TR, Ascher JA, et al. (2008). Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 10: 323-333. (Pubitemid 351637697)
19. Carney SM, Goodwin GM (2005). Lithium-a continuing story in the treatment of bipolar disorder. Acta Psychiatr Scand Suppl:7-12. (Pubitemid 40604344)
20. Castells X, Vallano A, Rigau D, Pérez J, Casas M, Capellà D (2006). Trends in lithium prescription in Spain from 1985 to 2003. J Affect Disord 91: 273-276.
21. Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ (2010). Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Hum Psychopharmacol 25:179-186.
22. Cipriani A, Rendell J, Geddes JR (2010). Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol 24:1729-1738.
23. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML (1994). A reevaluation of risk of in utero exposure to lithium. JAMA 271:146-150. (Pubitemid 24020593)
24. Cohrs S, Gade K, Meier A, Jordan W, Falkai P, Rüther E, Rodenbeck A (2010). Quetiapine improves sleep disturbance in acute bipolar disorder: a case series. Pharmacopsychiatry 43:154-155.
25. Datto C, Berggren L, Patel JB, Eriksson H (2009). Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-releasequetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 31:492-502.
26. Fountoulakis KN (2010). An update of evidence-based treatment of bipolar depression: where do we stand? Curr Opin Psychiatry 23:19-24.
27. Geddes JR, Calabrese JR, Goodwin GM (2009). Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 194:4-9.
28. Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, et al.; Balance Investigators and Collaborators (2010). Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 375:385-395.
29. Gerrett D, Lamont T, Paton C, Barnes TR, Shah A (2010). Prescribing and monitoring lithium therapy: summary of a safety report from the National Patient Safety Agency. BMJ 341:c6258.
30. Gershon S, Chengappa KN, Malhi GS (2009). Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord 11 (Suppl 2):34-44.
31. Goldberg JF, Brooks JO, Kurita K, Hoblyn JC, Ghaemi SN, Perlis RH, et al. (2009). Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 70:155-162.
32. Goodwin GM. Consensus Group of the British Association for Psychopharmacology (2009). Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 23:346-388.
33. Goodwin GM, Young AH (2003). The British Association for Psychopharmacology guidelines for treatment of bipolar disorder: a summary. J Psychopharmacol 17:3-6. (Pubitemid 38090023)
34. Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, et al. (2004). A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65:432-441.
35. Grunze HC, Normann C, Langosch J, Schaefer M, Amann B, Sterr A, et al. (2001). Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J Clin Psychiatry 62:464-468. (Pubitemid 32717880)
36. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, et al.; World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Bipolar Disorders (2002). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: treatment of bipolar depression. World J Biol Psychiatry 3:115-124.
37. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, et al.; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2003). The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders. Part II: Treatment of Mania. World J Biol Psychiatry 4:5-13.
38. Grunze H, Kasper S, Goodwin G, Bowden C, Möller HJ. WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2004). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders. Part III: maintenance treatment. World J Biol Psychiatry 5:120-135. (Pubitemid 44121706)
39. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, Kasper S (2009). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 10: 85-116.
40. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, Kasper S. WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010). The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 11:81-109.
41. Gyulai L, Bowden CL, McElroy SL, Calabrese JR, Petty F, Swann AC, et al. (2003). Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28:1374-1382. (Pubitemid 41070909)
42. Hirschfeld RM, Allen MH, McEvoy JP, Keck PE, Russell JM (1999). Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry 60:815-818.
43. Jentink J, Dolk H, Loane MA, Morris JK,Wellesley D, Garne E, De Jong-Van Den Berg L. EUROCAT Antiepileptic Study Working Group (2010). Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ 341:c6581.
44. Joffe H, Cohen LS, Suppes T, Hwang CH, Molay F, Adams JM, et al. (2006). Longitudinal follow-up of reproductive and metabolic features of valproateassociated polycystic ovarian syndrome features: a preliminary report. Biol Psychiatry 60:1378-1381. (Pubitemid 44838532)
45. Keck PE, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, et al.; Aripiprazole Study Group (2007). Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 68:1480-1491. (Pubitemid 350073394)
46. Kessing LV, Hansen MG, Andersen PK (2004). Course of illness in depressive and bipolar disorders. Naturalistic study, 1994-1999. Br J Psychiatry 185:372-377. (Pubitemid 39482072)
47. Kupfer DJ, Frank E, Grochocinski VJ, Luther JF, Houck PR, Swartz HA (2000). Stabilization in the treatment of mania, depression and mixed states. Acta Neuropsychiatrica 12:110-114.
48. Lim PZ, Tunis SL, Edell WS, Jensik SE, Tohen M (2001). Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disord 3:165-173. (Pubitemid 32842741)
49. Lin D, Mok H, Yatham LN (2006). Polytherapy in bipolar disorder. CNS Drugs 20:29-42. (Pubitemid 43061720)
50. Litchfield HR (1960). Aminophenylpyridone, a new mood-stabilizing drug. Arch Pediatr 77:133-137.
51. Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, et al. (2009). A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 11:827-839.
52. McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KD, Altshuler LL, et al. (2000). Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 47:1025-1033. (Pubitemid 30336210)
53. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH (2002). Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary singleblind study. Bipolar Disord 4:207-213. (Pubitemid 34591247)
54. McIntyre RS, Konarski JZ, Jones M, Paulsson B (2007). Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms. J Affect Disord 100 (Suppl 1):S5-S14. (Pubitemid 46818457)
55. Melander H, Ahlqvist RJ, Meijer G, Beermann B (2003). Evidence based medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326:1171-1173. (Pubitemid 36649049)
56. Mojtabai R, Olfson M (2010). National trends in psychotropic medication: polypharmacy in office-based psychiatry. Arch Gen Psychiatry 67:26-36.
57. Murray CJ, Lopez AD (1997). Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349: 1498-1504. (Pubitemid 27216360)
58. National Institute for Health and Clinical Excellence (2004). NICE clinical guideline 38 bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. London, UK: National Institute for Health and Clinical Excellence; Available at: www.nice.org.uk/CG038.
59. National Institute For Health and Clinical Excellence (2006). NICE clinical guideline 38 Biploar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Available at: http://www.nice.org.uk/CG038.
60. Newcomer JW (2007). Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68 (Suppl 4):8-13. (Pubitemid 46762118)
61. Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN (2005). Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry 162:2162-2170. (Pubitemid 41598272)
62. Niufan G, Tohen M, Qiuqing A, Fude Y, Pope E, McElroy H, et al. (2008). Olanzapine versus lithium in the acute treatment of bipolar mania: a doubleblind, randomized, controlled trial. J Affect Disord 105:101-108. (Pubitemid 350245681)
63. Nivoli AM, Pacchiarotti I, Rosa AR, Popovic D, Murru A, Valenti M, et al. (2011). Gender differences in a cohort study of 604 bipolar patients: the role of predominant polarity. J Affect Disord 133:443-449.
64. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V (2010). Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 68:156-162.
65. Rybakowski JK (2007). Two generations of mood stabilizers. Int J Neuropsychopharmacol 10:709-711.
66. Sachs GS, Koslow CL, Ghaemi SN (2000). The treatment of bipolar depression. Bipolar Disord 2:256-260.
67. Schmidtke A, Bille-Brahe U, Deleo D, Kerkhof A, Bjerke T, Crepet P, et al. (1996). Attempted suicide in Europe: rates, trends and sociodemographic characteristics of suicide attempters during the period 1989-1992. Results of the WHO/EURO Multicentre Study on Parasuicide. Acta Psychiatr Scand 93:327-338. (Pubitemid 26189155)
68. Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, Bowden CL (2010). Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord 122:1-9.
69. Suppes T, Dennehy EB, Swann AC, Bowden CL, Calabrese JR, Hirschfeld RM. Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder (2002). Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 63: 288-299. (Pubitemid 34456355)
70. Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese Jr. Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder (2005). The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 66: 870-886. (Pubitemid 41032829)
71. Suppes T, Kelly DI, Keck PE, McElroy SL, Altshuler LL, Mintz J, et al. (2007). Quetiapine for the continuation treatment of bipolar depression: naturalistic prospective case series from the Stanley Bipolar Treatment Network. Int Clin Psychopharmacol 22:376-381. (Pubitemid 47530843)
72. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Trial 127 Investigators (2009). Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 166:476-488.
73. Sussman N, Mullen J, Paulsson B, Va°geröM (2007). Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania. J Affect Disord 100 (Suppl 1):S55-S63. (Pubitemid 46818458)
74. Thase ME, Macfadden W,Weisler RH, Chang W, Paulsson B, Khan A. BOLDER II Study Group (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 26:600-609. (Pubitemid 44772737)
75. Tognoni G (1999). Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Italian Collaborative Study Group on the Outcome of Severe Mental Disorders. Eur J Clin Pharmacol 55:685-690.
76. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, et al. (2003a). Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 160: 1263-1271. (Pubitemid 41070942)
77. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. (2003b). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60:1079-1088. (Pubitemid 37429647)
78. Tohen M, GreilW, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. (2005). Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 162:pp. 1281-1290. (Pubitemid 40905578)
79. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, et al. (2006). Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 163:247-256. (Pubitemid 44480844)
80. Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M (2008). Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry 69:1776-1789.
81. Vieta E, Panicali F, Goetz I, Reed C, Comes M, Tohen M, Board EA (2008a). Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study. J Affect Disord 106:63-72.
82. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M (2008b). Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 109:251-263.
83. Wilting I, Souverein PC, Nolen WA, Egberts AC, Heerdink ER (2008). Changes in outpatient lithium treatment in the Netherlands during 1996-2005. J Affect Disord 111:94-99.
84. Wine JN, Sanda C, Caballero J (2009). Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. Ann Pharmacother 43:707-713.
85. Wolfsperger M, Greil W, Rössler W, Grohmann R (2007). Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. J Affect Disord 99:9-17. (Pubitemid 46275019)
86. Woods TM, Eichner SF, Franks AS (2004). Weight gain mitigation with topiramate in mood disorders. Ann Pharmacother 38:887-891. (Pubitemid 38509072)
87. Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, et al.; Canadian Network for Mood and Anxiety Treatments (2005). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 7 (Suppl 3):5-69. (Pubitemid 41065248)
88. Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, et al.; Guidelines Group, CANMAT (2006). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 8:721-739. (Pubitemid 44824712)
89. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, et al. (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 11:225-255.
90. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, et al.; EMBOLDEN I (Trial 001) Investigators (2010). A double-blind, placebocontrolled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 71:150-162.